Prevention of High Altitude Pulmonary Edema

University of Zurich (UZH)

Status and phase: Completed; Phase 2; Phase 1

Conditions: High Altitude Pulmonary Edema

Treatments: Drug: tadalafil 10mg bid; Drug: dexamethasone 8 mg bid

Study type: Interventional

Funder types: Other

Identifiers

NCT00274430

margherita03

Details and patient eligibility

About

A double-blind placebo controlled study

• To compare the effect of tadalafil and dexamethasone versus placebo on Ppa and pulmonary edema formation in subjects susceptible to HAPE.
• To investigate the effect of dexamethasone on alveolar fluid clearance, as assessed by measurement of the nasal potential difference, and prevention of HAPE.
• To investigate the effect of the tadalafil and dexamethasone versus placebo on the dynamic CBF autoregulation properties and on the development of AMS in HAPE susceptible subjects.

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• At least one previous episode of high altitude pulmonary edema

Exclusion criteria

• pulmonary arterial hypertension
• congenital heart disease
• any chronic lung disease

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind